Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Start Booster Program for Ages 12-17 from as Early as April
March 14, 2022
- Japan to Decide on 4th COVID Shot Based on Science, Overseas Reponses: Minister
March 11, 2022
- MHLW to Conduct Follow-Up Survey on Pediatric COVID Vaccinations
March 10, 2022
- Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- MHLW Drafts Guidelines for Evaluating SaMD Used for Behavioral Modification
March 9, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
March 7, 2022
- MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion
March 7, 2022
- MHLW Panel Endorses Takeda’s HAE Med and More, Drops AZ’s Asthma Drug
March 4, 2022
- MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts
March 4, 2022
- Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
- Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
March 4, 2022
- Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
- Japan Ponders Fourth COVID-19 Vaccine Shot after Autumn
March 3, 2022
- Pfizer’s Paxlovid Listed in MHLW’s COVID-19 Guide
March 3, 2022
- Yervoy Infusion Time Changed for Melanoma: Label Update
March 2, 2022
- Japan Cabinet OKs Draft Bill to Amend PMD Law
March 2, 2022
- Pfizer’s Paxlovid Can Now Be Used Across Japan on In-Hospital Dispensing
March 1, 2022
- Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
March 1, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…